The deal hands Genmab a drug that showed the potential in earlier testing to extend survival in head and neck cancer when ...

Genmab acquires Merus for $8B, boosting cancer drug pipeline with petosemtamab. Check out what this deal means for GMAB and ...

Only 1 in 10 of the prescriptions filled in the U.S. are for brand-name drugs; the vast majority are for generics, which are ...

The centerpiece of the acquisition is petosemtamab, Merus’ bispecific antibody targeting EGFR and LGR5, which in May ...

The Danish company Genmab plans to buy Merus, the maker of a promising head and neck cancer drug, in a deal worth roughly $8 ...

Genmab acquires Merus for $8bn, adding promising oncology asset petosemtamab. Check out my thoughts on this deal and my ...

Nandita Vijayasimha, Bengaluru Tuesday, September 30, 2025, 08:00 Hrs [IST] ...

FDA recommends that IO Biotech not submit a Biologics License Application (BLA) based on the data from the IOB-013 clinical trial Company plans to design new registrational study for Cylembio for the ...

Explore the latest advancements in muscle-invasive bladder cancer treatment, including immunotherapy and novel therapies ...

IO Biotech (IOBT) stock slumped 77% by Monday afternoon after the company announced that the U.S. Food and Drug Administration (FDA) recommended that the firm conduct another trial before submitting ...

The cost of a drug used to treat a rare liver disorder rose by more than 1,500 percent, according to Sanders’s office.

Investing.com -- Danish biotechnology company Genmab (CSE:GMAB) on Monday said it will acquire Merus N.V., a Dutch biotech, in an $8 billion all-cash transaction, paying $97 per share. Shares of the ...